SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

Kim, SY; Kim, SM; Chang, HJ; Kim, BW; Lee, YS; Park, CS; Park, KC; Chang, HS

Chang, HS (reprint author), Yonsei Univ, Coll Med, Gangnam Severance Hosp, Thyroid Canc Ctr,Dept Surg, Seoul 120720, South Korea.; Park, KC; Chang, HS (reprint author), Yonsei Univ, Coll Med, Dept Surg, 50-1 Yonsei Ro, Seoul 120752, South Korea.; Chang, H

BMC CANCER, 2018; 18 ():

Abstract

Background: In the last decade, several tyrosine kinase inhibitors (TKIs), which disrupt pathways involved in the proliferation and tumorigenesis of t......

Full Text Link